PD-1/VEGF bispecific antibody is named as a drug or biological intervention in 2 clinical trials in our China trial register, none of which are currently recruiting. The lead sponsor is Sichuan Baili Pharmaceutical Co., Ltd.. Registered phase: Phase 2/3. Conditions studied include Squamous Non-small-cell Lung Cancer; Non-squamous Non-small Cell Lung Cancer.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07739186 | A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06) (ClinicalTrials.gov ↗) Non-squamous Non-small Cell Lung Cancer |
Phase 2/3 | Not yet open |
| NCT07739199 | A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05) (ClinicalTrials.gov ↗) Squamous Non-small-cell Lung Cancer |
Phase 2/3 | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Squamous Non-small-cell Lung Cancer | 1 |
| Non-squamous Non-small Cell Lung Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| Sichuan Baili Pharmaceutical Co., Ltd. | 2 |
| Register | PD-1/VEGF bispecific antibody trials |
|---|---|
| Clinical trials in China | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how PD-1/VEGF bispecific antibody works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists PD-1/VEGF bispecific antibody (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.